Increased expression of TGF-β receptors by scleroderma fibroblasts:: Evidence for contribution of autocrine TGF-β signaling to scleroderma phenotype

被引:221
作者
Kawakami, T [1 ]
Ihn, H [1 ]
Xu, WD [1 ]
Smith, E [1 ]
LeRoy, C [1 ]
Trojanowska, M [1 ]
机构
[1] Med Univ S Carolina, Div Rheumatol & Immunol, Charleston, SC 29425 USA
关键词
collagen type I; fibrosis;
D O I
10.1046/j.1523-1747.1998.00073.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Scleroderma fibroblasts exhibit numerous phenotypic differences when compared with healthy skin fibroblasts. Some of these differences, in particular overexpression of collagen type I and other extracellular matrix proteins, parallel the effect of transforming growth factor-beta (TGF-beta) on dermal fibroblasts, suggesting that the scleroderma fibroblast phenotype may result from activation of autocrine TGF-beta signaling. To test this hypothesis we examined the role of TGF-beta Type I and Type II receptors in regulating collagen type I transcription, We have shown that overexpression of either Type I or Type II receptors significantly (3-4-fold) increases alpha 2 (I) collagen promoter activity in transient transfection assays in dermal fibroblasts. Addition of anti-TGF-beta antibody abolished, whereas addition of plasmin enhanced, the stimulatory effect of receptor overexpression on collagen promoter activity, suggesting that this effect depends on autocrine TGF-beta, Moreover, these cotransfection experiments indicated that expression levels of TGF-beta receptors is a limiting factor in the autocrine regulation of collagen type I transcription by TGF-beta. Comparison of the TGF-beta receptor Type I and Type II mRA expression levels in scleroderma and normal fibroblasts have indicated elevated expression (2-fold) of both receptor types in scleroderma cells, which correlated with increased binding of TGF-beta. Significantly, elevated TGF-beta receptor levels correlated with elevated alpha 2 (I) collagen mRNA levels. These results suggest that the elevated production of collagen type I by scleroderma fibroblasts results from overexpression of TGF-beta receptors.
引用
收藏
页码:47 / 51
页数:5
相关论文
共 38 条
  • [1] EXPRESSION AND FUNCTION OF SURFACE-ANTIGENS ON SCLERODERMA FIBROBLASTS
    ABRAHAM, D
    LUPOLI, S
    MCWHIRTER, A
    PLATERZYBERK, C
    PIELA, TH
    KORN, JH
    OLSEN, I
    BLACK, C
    [J]. ARTHRITIS AND RHEUMATISM, 1991, 34 (09): : 1164 - 1172
  • [2] ATTISANO I, 1994, BIOCHIM BIOPHYS ACTA, V1222, P71
  • [3] TRANSFORMING GROWTH-FACTOR-BETA IN DISEASE - THE DARK SIDE OF TISSUE-REPAIR
    BORDER, WA
    RUOSLAHTI, E
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (01) : 1 - 7
  • [4] EXCESS MATRIX ACCUMULATION IN SCLERODERMA IS CAUSED PARTLY BY DIFFERENTIAL REGULATION OF STROMELYSIN AND TIMP-1 SYNTHESIS
    BOUGHARIOS, G
    OSMAN, J
    BLACK, C
    OLSEN, I
    [J]. CLINICA CHIMICA ACTA, 1994, 231 (01) : 69 - 78
  • [5] BRAND T, 1993, J BIOL CHEM, V268, P11500
  • [6] BUCKINGHAM RB, 1978, J LAB CLIN MED, V92, P5
  • [7] ONCOSTATIN-M STIMULATES COLLAGEN AND GLYCOSAMINOGLYCAN PRODUCTION BY CULTURED NORMAL DERMAL FIBROBLASTS - INSENSITIVITY OF SCLERODERMAL AND KELOIDAL FIBROBLASTS
    DUNCAN, MR
    HASAN, A
    BERMAN, B
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1995, 104 (01) : 128 - 133
  • [8] Differential regulation of transcription and transcript stability of pro-alpha 1(I) collagen and fibronectin in activated fibroblasts derived from patients with systemic scleroderma
    Eckes, B
    Mauch, C
    Huppe, G
    Krieg, T
    [J]. BIOCHEMICAL JOURNAL, 1996, 315 : 549 - 554
  • [9] TRANSFORMING GROWTH-FACTOR-BETA - SELECTIVE INCREASE IN GLYCOSAMINOGLYCAN SYNTHESIS BY CULTURES OF FIBROBLASTS FROM PATIENTS WITH PROGRESSIVE SYSTEMIC-SCLEROSIS
    FALANGA, V
    TIEGS, SL
    ALSTADT, SP
    ROBERTS, AB
    SPORN, MB
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1987, 89 (01) : 100 - 104
  • [10] CONTROL OF IL-6 EXPRESSION AND RESPONSE IN FIBROBLASTS FROM PATIENTS WITH SYSTEMIC-SCLEROSIS
    FEGHALI, CA
    BOST, KL
    BOULWARE, DW
    LEVY, LS
    [J]. AUTOIMMUNITY, 1994, 17 (04) : 309 - 318